Alpine Immune Sciences is taking a unique approach to immunology to treat cancer, autoimmune and inflammatory diseases. Alpine is using protein engineering strategies, such as their proprietary directed evolution platform, to turn immune proteins into multi-targeted therapeutics that can modulate the human immune system. The platform is highly flexible and has been used by Alpine to enhance the activity of native IgSF and TNFSF, which can then be used for many therapeutic formats like Fc fusion, cell therapy or monoclonal antibodies. Therefore, a single directed evolution campaign can have several final formats. Alpine’s diverse pipeline consists of both wholly-owned programs and partnered programs in development for immuno-oncology and inflammatory diseases such as Lupus. 

<p>Alpine Immune Sciences is taking a unique approach to immunology to treat cancer, autoimmune and inflammatory diseases. Alpine is using protein engineering strategies, such as their proprietary directed evolution platform, to turn immune proteins into multi-targeted therapeutics that can modulate the human immune system. The platform is highly flexible and has been used by Alpine to enhance the activity of native IgSF and TNFSF, which can then be used for many therapeutic formats like Fc fusion, cell therapy or monoclonal antibodies. Therefore, a single directed evolution campaign can have several final formats. Alpine’s diverse pipeline consists of both wholly-owned programs and partnered programs in development for immuno-oncology and inflammatory diseases such as Lupus. </p>


Alpine Immune Sciences

Founded: 2015
Location: Seattle, WA
Employee range: 50 - 200
Clinical stage: Clin2
Therapy area: Systemic lupus erythematosus (partner: AbbVie)
Drug types: IMM, NPH, HEM
Lead product: Acazicolcept
Funding: $100M stock Sep 2022; $91M stock Sep 2021; $48M Jun 2016

Drug notes:

About:

Jobs: